USFDA completes post-marketing Adverse Drug Experience inspection at Granules India’s arm

04 Aug 2023 Evaluate

United States Food and Drug Administration (USFDA) has successfully completed post-marketing Adverse Drug Experience (PADE) inspection at Granules India’s wholly owned foreign subsidiary -- Granules Pharmaceuticals, Inc. (GPI). The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023. The inspection was closed with zero observations.

This inspection covered the Granules’ PADE surveillance, receipts, evaluations, processing and reporting system for the marketed drug products worldwide. This is Granules India’s fourth FDA audit since March with zero observations - a testament to Granules India's unwavering commitment to ensuring the highest level of patient safety and product quality.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

585.50 -7.40 (-1.25%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.